Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serono Luveris review

Executive Summary

Serono's NDA (21-322) for recombinant luteinizing hormone product Luveris (lutropin alpha for inj.) will be reviewed by FDA's Reproductive Health Drugs Advisory Committee on Sept. 30 for concomitant administration with recombinant human follicle stimulating hormone for the induction of ovulation in infertile women with severe luteinizing hormone or follicle stimulating hormone deficiency. The meeting on both days will begin at 8:30 a.m. at the Hilton in Gaithersberg, Md. [To 1watch a webcast or live video of these meetings, go to FDAAdvisoryCommittee.com]....
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS042338

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel